Repertoire Immune Medicines has landed its fourth Big Pharma collaboration, this time with Eli Lilly in a deal worth about $1.93 billion.
Why it matters: Such partnerships could help the company attract investors when it begins fundraising a Series C later this year, CEO Torben Straight Nissen tells Axios Pro.
